Genetically engineered dendritic cells for T cell activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and vaccines for SARS-CoV-2, such as mRNA-based vaccines, are not effective in enhancing SARS-CoV-2 specific T cells in all individuals and have adverse side effects, while traditional therapies may not adequately address chronic infections and emerging variants, particularly in populations with exhausted T cells.
Innovation Solution
Development of genetically engineered dendritic cells (DCs) derived from human induced pluripotent stem cells (HiPSCs), specifically DC-COV19, which integrate SARS-CoV-2-specific viral constructs, including the spike protein linked with HLA-DR, to activate robust and specific CD4+ and CD8+ T cells, providing a broad-spectrum therapeutic approach for current and new variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA-based vaccines are used to enhance SARS-CoV-2 specific T cells, then immune response is improved, but adverse side effects occur and effectiveness is limited in certain populations
Solution Approach 1:
The patent uses dendritic cells as intermediary carriers to deliver SARS-CoV-2 antigens to T cells. Instead of directly injecting mRNA into the body, the antigens are presented by dendritic cells through MHC molecules, creating a controlled immune stimulation that reduces adverse effects while maintaining effectiveness. The dendritic cells act as a bridge between the antigen and the immune system.
Solution Approach 2:
The dendritic cells are engineered to autonomously present antigens and activate T cells without requiring continuous external stimulation. The genetically modified dendritic cells continuously express SARS-CoV-2 antigens and HLA molecules, enabling them to self-sustain the immune activation process and provide long-lasting protective immunity.
2Adaptability or versatility
If traditional therapies are used to treat infections, then treatment is provided, but they do not adequately address chronic infections and emerging variants
Solution Approach 1:
The dendritic cells are engineered with universal features that enable them to address multiple pathogens and variants. By incorporating conserved viral proteins such as nucleocapsid and polymerase alongside variant-specific spike protein variants, the therapy creates broadly protective T cell responses that can recognize and respond to diverse SARS-CoV-2 variants and related coronaviruses.
Solution Approach 2:
The therapy dynamically adapts to emerging variants by incorporating updated viral protein sequences into the dendritic cell engineering. The system can be reconfigured with new antigen sequences as variants emerge, allowing the immune response to evolve alongside the pathogen while maintaining effectiveness against chronic infections through sustained T cell activation.
3Reliability
If genetically engineered DCs are developed to activate T cells, then T cell activation is improved, but treatment complexity increases
Solution Approach 1:
The treatment process is segmented into distinct modular steps: dendritic cell isolation and culture, genetic modification with viral antigens, quality control testing, and administration. Each step can be independently optimized and controlled, making the complex process manageable and scalable. The segmentation allows for standardized protocols that reduce operational complexity while maintaining high T cell activation effectiveness.
Data Source
AI summary
Provided are genetically engineered DC probes/epitopes that are able to stimulate high numbers of a pathogenic or viral, or degenerative protein (such as the functional spike (Sp), membrane (M), and nucleocapsid (N) protein and amyloid beta and tau protein) and produce protein-specific CD4+ and CD8+ T cells ex vivo, which can then be adaptively administered to patients to treat a variety of pathogenic infections, degenerative disorder, including viral infections.